Samsung Biologics Co Ltd
KRX:207940
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
EV/EBITDA Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (42.8), the stock would be worth ₩1 422 372.54 (42% upside :side from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 30.1 | ₩1 000 000 |
0%
|
| 3-Year Average | 42.8 | ₩1 422 372.54 |
+42%
|
| 5-Year Average | 53.7 | ₩1 783 803.48 |
+78%
|
| Industry Average | 23.9 | ₩793 003.9 |
-21%
|
| Country Average | 8.5 | ₩283 518.83 |
-72%
|
Forward EV/EBITDA
Today's price vs future EBITDA
| Current Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
₩81.4T
|
/ |
Dec 2025
₩2.7T
|
= |
|
|
₩81.4T
|
/ |
Dec 2026
₩3T
|
= |
|
|
₩81.4T
|
/ |
Dec 2027
₩3.4T
|
= |
|
|
₩81.4T
|
/ |
Dec 2028
₩3.8T
|
= |
|
Forward EV/EBITDA shows whether today's EV/EBITDA still looks high or low once future EBITDA are taken into account.
